Sunmax Biotechnology Co., Ltd. (TPEX:4728)
Taiwan · Delayed Price · Currency is TWD 390.50
+1.50 (0.39%)
Nov 5, 2026, 2:31 PM CST
Sunmax Biotechnology Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 21,268 | 21,567 | 15,250 | 11,110 | 7,407 | 4,499 | |
Market Cap Growth | -0.64% | 41.43% | 37.26% | 50.00% | 64.65% | 2.61% |
Enterprise Value | 20,583 | 20,955 | 14,751 | 10,469 | 6,785 | 3,756 |
Last Close Price | 390.50 | 383.90 | 263.95 | 185.38 | 118.63 | 69.55 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 26.24 | 29.72 | 22.45 | 17.76 | 13.88 | 18.31 |
PS Ratio | 9.69 | 10.64 | 8.39 | 6.58 | 5.29 | 4.34 |
PB Ratio | 14.86 | 13.33 | 10.08 | 7.79 | 5.59 | 4.39 |
P/TBV Ratio | 14.95 | 13.41 | 10.12 | 7.82 | 5.61 | 4.41 |
P/FCF Ratio | 24.43 | 28.14 | 28.82 | 15.00 | 15.12 | - |
P/OCF Ratio | 22.17 | 26.11 | 27.18 | 13.09 | 11.49 | 18.49 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 9.38 | 10.34 | 8.11 | 6.20 | 4.85 | 3.63 |
EV/EBITDA Ratio | 17.06 | 19.59 | 14.83 | 11.18 | 8.47 | 9.45 |
EV/EBIT Ratio | 18.82 | 20.99 | 15.91 | 11.70 | 8.84 | 10.22 |
EV/FCF Ratio | 23.65 | 27.35 | 27.88 | 14.13 | 13.85 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.08 | 0.07 | 0.10 | 0.12 | 0.05 | 0.10 |
Debt / EBITDA Ratio | 0.09 | 0.11 | 0.14 | 0.17 | 0.08 | 0.23 |
Debt / FCF Ratio | 0.12 | 0.16 | 0.27 | 0.23 | 0.13 | - |
Net Debt / Equity Ratio | -0.48 | -0.52 | -0.48 | -0.56 | -0.57 | -0.57 |
Net Debt / EBITDA Ratio | -0.58 | -0.79 | -0.72 | -0.85 | -0.94 | -1.46 |
Net Debt / FCF Ratio | -0.79 | -1.10 | -1.36 | -1.07 | -1.54 | 59.56 |
Asset Turnover | 1.00 | 0.96 | 0.86 | 0.86 | 0.85 | 0.73 |
Inventory Turnover | 2.61 | 2.82 | 2.70 | 3.39 | 3.23 | 3.53 |
Quick Ratio | 1.97 | 3.28 | 2.72 | 2.12 | 2.52 | 2.06 |
Current Ratio | 2.55 | 3.89 | 3.32 | 2.36 | 2.78 | 2.36 |
Return on Equity (ROE) | 60.67% | 46.37% | 46.24% | 45.48% | 45.45% | 25.69% |
Return on Assets (ROA) | 31.13% | 29.58% | 27.24% | 28.30% | 29.29% | 16.12% |
Return on Invested Capital (ROIC) | 186.31% | 91.08% | 92.67% | 102.19% | 103.94% | 91.36% |
Return on Capital Employed (ROCE) | 68.50% | 54.60% | 52.50% | 52.60% | 52.30% | 31.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.81% | 3.36% | 4.46% | 5.63% | 7.21% | 5.46% |
FCF Yield | 4.09% | 3.55% | 3.47% | 6.67% | 6.62% | -0.22% |
Dividend Yield | 3.10% | 3.06% | 4.14% | 5.39% | 6.98% | 5.33% |
Payout Ratio | 159.05% | 87.05% | 88.18% | 82.69% | 44.89% | 44.34% |
Buyback Yield / Dilution | -0.03% | 0.01% | -0.00% | 0.01% | -0.03% | 0.02% |
Total Shareholder Return | 3.07% | 3.06% | 4.14% | 5.40% | 6.96% | 5.35% |